Cardiovascular and kidney diseases are prevalent in patients with diabetes, causing substantial morbidity and mortality.1,2,3 Many hypoglycemic agents have been evaluated for cardiovascular and kidney protection beyond their originally designed hypoglycemic effects.4 Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were found to improve kidney and cardiovascular outcomes,5,6 with new trials ongoing and results emerging. This evidence concerns the gene GLP1R and diabetes mellitus.